Hinge Health Inc
NYSE:HNGE
Hinge Health Inc
Hinge Health Inc is a US-based company operating in Health Care Providers & Services industry. The company is headquartered in San Francisco, California. The company went IPO on 2025-05-22. Hinge Health, Inc. leverages software, including artificial intelligence (AI), to largely automate care for joint and muscle health. The firm has designed its TrueMotion platform to address a spectrum of musculoskeletal (MSK) care from acute injury to chronic pain, to post-surgical rehabilitation. Members receive personalized and automated MSK care through its AI-powered motion tracking technology. The company offers electrical nerve stimulation wearable device Enso, all designed and monitored by its AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Its platform offers a range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. Enso delivers electrical nerve stimulation designed to provide non-addictive and non-invasive pain relief.
Hinge Health Inc is a US-based company operating in Health Care Providers & Services industry. The company is headquartered in San Francisco, California. The company went IPO on 2025-05-22. Hinge Health, Inc. leverages software, including artificial intelligence (AI), to largely automate care for joint and muscle health. The firm has designed its TrueMotion platform to address a spectrum of musculoskeletal (MSK) care from acute injury to chronic pain, to post-surgical rehabilitation. Members receive personalized and automated MSK care through its AI-powered motion tracking technology. The company offers electrical nerve stimulation wearable device Enso, all designed and monitored by its AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Its platform offers a range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. Enso delivers electrical nerve stimulation designed to provide non-addictive and non-invasive pain relief.
Revenue Beat: Hinge Health delivered Q4 revenue of $171 million, up 46% year-over-year and well above its $155–157 million guidance. Full-year 2025 revenue was $588 million, up 51% and 15% above the IPO analyst consensus.
Profitability Milestone: Operating margin reached 28% in Q4 and 20% for the year. Free cash flow margin hit 31% for 2025, meeting the company’s IPO target earlier than planned.
Guidance Raised: 2026 revenue guidance of $732–742 million (25% growth) is $39 million ahead of sell-side consensus. Profit guidance was also raised.
AI Investments: Significant efficiency gains from AI-powered tools enabled serving 47% more members in 2025 without increasing care team costs. Member NPS is at an all-time high.
Membership & Client Growth: Contracted lives grew 24% to 24.6 million and clients grew 25% to 2,800+, including 53% of the Fortune 100. Annual client retention remained strong at 97%.
HingeSelect Expansion: HingeSelect provider network is showing early success, with 85% of members moving to conservative care and major health plans endorsing the offering, but material revenue is not expected before 2027.
Operating Leverage: Operating expenses dropped to 63% of revenue for 2025 from 84% in 2024, reflecting improved scalability and efficiency.
